Sign In
Sign Out
My Account
Subscribe
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
Special reports
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
Home
»
Authors
»
Nuala Moran
Articles by Nuala Moran
Eurogene Acquires Quattrogene, Phase II Product In Stock Deal
Jan. 31, 2001
By
Nuala Moran
London Exchange Might Ease Listing Rules For Young Firms
Jan. 24, 2001
By
Nuala Moran
Strong Placebo Effect In Phase II Causes Failed Phytopharm Trial
Jan. 24, 2001
By
Nuala Moran
IsoTis Completes Implants Of Autologous Living Bone Tissue
Jan. 24, 2001
By
Nuala Moran
Strong Placebo Effect In Phase II Causes Failed Phytopharm Trial
Jan. 24, 2001
By
Nuala Moran
IsoTis Completes Implants Of Autologous Living Bone Tissue
Jan. 24, 2001
By
Nuala Moran
London Exchange Might Ease Listing Rules For Young Firms
Jan. 24, 2001
By
Nuala Moran
Avidex Completes £10M Funding For Programs In T-Cell Receptors
Jan. 17, 2001
By
Nuala Moran
Cambridge Drug Eyes Licensing Deals Following £7.5M Financing
Jan. 17, 2001
By
Nuala Moran
SkyePharma Exchanges Share Of Phase III Risk, Reward For $30M
Jan. 17, 2001
By
Nuala Moran
Previous
1
2
…
501
502
503
504
505
506
507
508
509
Next
BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe